Faculty, Staff and Student Publications
Publication Date
5-1-2023
Journal
JCO Precision Oncology
Abstract
PURPOSE: Philadelphia-like (Ph-like) B-cell ALL is a high-risk subtype of B-cell ALL that shares a gene expression profile with Ph-positive ALL, but without a
PATIENTS AND METHODS: We performed a retrospective review of patients with B-cell ALL treated at MD Anderson Cancer Center to identify recurrent genetic fusions commonly seen in Ph-like ALL and focus on patients treated with TKI.
RESULTS: We identified 23 patients with recurrent genetic fusions commonly seen in Ph-like ALL; 14 had
CONCLUSION: Understanding the genomics of B-cell ALL is important for disease prognostication and for precise treatment planning. Besides conventional cytogenetics and directed FISH testing, multiplex fusion assays can help identify recurrent chromosomal translocations that are seen in patients with Ph-like ALL. Early initiation of TKI appears beneficial; larger studies are required to fully understand the benefit of TKI and to design rational combination therapies for these patients.
Keywords
Humans, Gene Rearrangement, In Situ Hybridization, Fluorescence, Retrospective Studies, Transcriptome, Tyrosine Kinase Inhibitors, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
PMID: 37196217